Suchergebnisse - (Person:"Lu, Qiong")

PubPharm (16)

1

Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system

enthalten in: MedComm | 2024

von Liang, Z. | Tong, J. | Wu, X. | +9

2

Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants

enthalten in: Journal of medical virology | 2024

von Liang, Z. | Tong, J. | Sun, Z. | +11

3

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector

enthalten in: Emerging microbes & infections | 2023

von Liang, Z. | Wu, X. | Wu, J. | +11

4

Analysis of SARS-CoV-2 variants B.1.617 : host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity

enthalten in: Emerging microbes & infections | 2022

von Zhang, L. | Li, Q. | Wu, J. | +19

5

The molecular basis for SARS-CoV-2 recognized by dog ACE2

enthalten in: ResearchSquare.com | 2022

von Zhang, Z. | Zhang, Y. | Liu, K. | +17

6

Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses

enthalten in: Signal transduction and targeted therapy | 2022

von Li, Q. | Zhang, L. | Liang, Z. | +13

7

The molecular basis for SARS-CoV-2 binding to dog ACE2

enthalten in: Nature communications | 2021

von Zhang, Z. | Zhang, Y. | Liu, K. | +19

8

Infectivity and antigenicity of SARS-CoV-2 B.1.617 variants

enthalten in: ResearchSquare.com | 2021

von Wang, Y. | Zhang, L. | Li, Q. | +19

9

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

enthalten in: Cell | 2021

von Li, Q. | Nie, J. | Wu, J. | +24

CommentIn: Signal Transduct Target Ther. 2021 Jul 27;6(1):284. - PMID 34315847

10

Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses

enthalten in: Cell discovery | 2021

von Nie, J. | Li, Q. | Zhang, L. | +21